Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 19 results.
User Information
Export Records
  1. 1.   Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
  2. Cecchini, Michael; Pilat, Mary Jo; Uboha, Nataliya; Azad, Nilofer S; Cho, May; Davis, Elizabeth J; Ahnert, Jordi Rodon; Tinoco, Gabriel; Shapiro, Geoffrey I; Khagi, Simon; Powers, Benjamin; Spencer, Kristen; Groisberg, Roman; Drappatz, Jan; Chen, Li; Das,Bishu; Bao, Xun; Li, Jing; Narayan, Azeet; Vu, Dennis; Patel, Abhijit; Niger, Monica; Doroshow, Deborah; Durecki, Diane; Boerner, Scott A; Bindra, Ranjit; Ivy, Percy; Shyr, Derek; Shyr, Yu; LoRusso, Patricia M
  3. Cancer. 2025, Feb 15; 131(4): e35755.
  1. 2.   Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
  2. Glade Bender, Julia L; Pinkney, Kerice; Williams,Mickey; Roy-Chowdhuri, Sinchita; Patton, David R; Coffey, Brent D; Reid, Joel M; Piao, Jin; Saguilig, Lauren; Alonzo, Todd A; Berg, Stacey L; Ramirez, Nilsa C; Fox, Elizabeth; Weigel, Brenda J; Hawkins, Douglas S; Mooney, Margaret M; Takebe, Naoko; Tricoli, James V; Janeway, Katherine A; Seibel, Nita L; Parsons, Donald W
  3. The Oncologist. 2024, May 30;
  1. 3.   Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer
  2. Furusawa, Takashi; Cavero, Renzo; Liu, Yue; Li, Haojian; Xu,Xia; Andresson,Thorkell; Reinhold, William; White, Olivia; Boufraqech, Myriem; Meyer,Thomas; Hartmann, Oliver; Diefenbacher, Markus E; Pommier, Yves; Weyemi, Urbain
  3. Molecular Carcinogenesis. 2024, Feb 27;
  1. 4.   A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
  2. Manzo, Julia; Puhalla, Shannon; Pahuja, Shalu; Ding, Fei; Lin, Yan; Appleman, Leonard; Tawbi, Hussein; Stoller, Ronald; Lee, James J; Diergaarde, Brenda; Kiesel, Brian F; Yu, Jing; Tan, Antoinette R; Belani, Chandra P; Chew, Helen; Garcia, Agustin A; Morgan, Robert J; Wahner Hendrickson, Andrea E; Visscher, Daniel W; Hurley, Rachel M; Kaufmann, Scott H; Swisher, Elizabeth M; Oesterreich, Steffi; Katz, Tiffany; Ji,Jay; Zhang, Yiping; Parchment, Ralph E; Chen, Alice; Duan, Wenrui; Giranda, Vincent; Shepherd, Stacie P; Ivy, S Percy; Chu, Edward; Beumer, Jan H
  3. Cancer Chemotherapy and Pharmacology. 2022, Apr 18; 89(5): 721-735.
  1. 5.   Exploring role of 5hmC as potential marker of chemoresistance
  2. Kharat,Suhas; Sharan,Shyam
  3. MOLECULAR & CELLULAR ONCOLOGY. 2020, Oct 22; 7(6): 1827904.
  1. 6.   Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-Schlafen 11and low-MGMT expression
  2. Rathkey, Daniel; Khanal, Manakamana; Murai, Junko; Zhang, Jingli; Sengupta, Manjistha; Jiang, Qun; Morrow, Betsy; Evans,Christine; Chari,Raj; Fetsch, Patricia; Chung, Hye-Jung; Xi, Liqiang; Roth, Mark; Filie, Armando; Raffeld, Mark; Thomas, Anish; Pommier, Yves; Hassan, Raffit
  3. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020, Jan 28; pii: S1556-0864(20)30035-6.
  1. 7.   PARP Inhibitor Sensitivity Does Not Depend on BAP1 but Is Enhanced by Temozolomide in MGMT Deficient Human Mesothelioma Cells
  2. Rathkey, D.; Khanal, M.; Murai, J.; Zhang, J.; Jiang, Q.; Morrow, B.; Evans, C.; Chari,Raj; Sengupta, M.; Thomas, A.; Pommier, Y.; Hassan, R.
  3. JOURNAL OF THORACIC ONCOLOGY. 2019, OCT; 14(10): S296-S296.
  1. 8.   Durvalumab in Combination with Olaparib in Patients with Relapsed Small Cell Lung Cancer: Results from a Phase II Study
  2. Thomas, Anish; Vilimas, Rasa; Trindade, Christopher; Erwin-Cohen,Rebecca; Roper, Nitin; Xi, Liqiang; Krishnasamy, Venkatesh; Levy, Elliot; Mammen, Andy; Nichols, Samantha; Chen, Yuanbin; Velcheti, Vamsidhar; Yin, Faye; Szabo, Eva; Pommier, Yves; Steinberg, Seth M; Trepel, Jane B; Raffeld, Mark; Young,Howard; Khan, Javed; Hewitt, Stephen; Lee, Jung-Min
  3. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019, AUG; 14(8): 1447-1457.
  1. 9.   A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses
  2. Zimmer, Alexandra S; Nichols,Erin; Cimino-Mathews, Ashley; Peer, Cody; Cao, Liang; Lee, Min-Jung; Kohn, Elise C; Annunziata, Christina M; Lipkowitz, Stanley; Trepel, Jane B; Sharma, Rajni; Mikkilineni, Lekha; Gatti-Mays, Margaret; Figg, William D; Houston, Nicole D; Lee, Jung-Min
  3. Journal for immunotherapy of cancer. 2019, Jul 25; 7(1): 197.
  1. 10.   BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation
  2. Zong, Dali; Adam, Salome; Wang, Yifan; Sasanuma, Hiroyuki; Callen, Elsa; Murga, Matilde; Day, Amanda; Kruhlak, Michael J.; Wong, Nancy; Munro, Meagan; Chaudhuri, Arnab Ray; Karim,Baktiar; Xia, Bing; Takeda, Shunichi; Johnson, Neil; Durocher, Daniel; Nussenzweig, Andre
  3. Molecular cell. 2019, MAR 21; 73(6): 1267-+.
  1. 11.   Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
  2. Karzai, Fatima; VanderWeele, David; Madan, Ravi A; Owens, Helen; Cordes, Lisa M; Hankin, Amy; Couvillon, Anna; Nichols, Erin; Bilusic, Marijo; Beshiri, Michael L; Kelly, Kathleen; Krishnasamy, Venkatesh; Lee, Sunmin; Lee, Min-Jung; Yuno, Akira; Trepel, Jane B; Merino, Maria J; Dittamore, Ryan; Marté, Jennifer; Donahue, Renee N; Schlom, Jeffrey; Killian, Keith J; Meltzer, Paul S; Steinberg, Seth M; Gulley, James L; Lee, Jung-Min; Dahut, William L
  3. Journal for immunotherapy of cancer. 2018, Dec 04; 6(1): 141.
  1. 12.   RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks.
  2. Dungrawala, Huzefa; Bhat, Kamakoti P; Le Meur, Rémy; Chazin, Walter J; Ding, Xia; Sharan, Shyam; Wessel, Sarah R; Sathe, Aditya A; Zhao, Runxiang; Cortez, David
  3. Molecular cell. 2017, Aug 3; 67(3): 374-+.
  1. 13.   Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types
  2. Niu, Jing; Scheuerell, Christie; Mehrotra, Shailly; Karan, Sharon; Puhalla, Shannon; Kiesel, Brian F; Ji, Jay; Chu, Edward; Gopalakrishnan, Mathangi; Ivaturi, Vijay; Gobburu, Jogarao; Beumer, Jan H
  3. Journal of clinical pharmacology. 2017, Aug; 57(8): 977-987.
  1. 14.   Advances in using PARP inhibitors to treat cancer
  2. Kummar, S.; Chen, A.; Parchment, R. E.; Kinders, R. J.; Ji, J.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Bmc Medicine. 2012, Mar; 10
  1. 15.   Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
  2. Ji, J. P.; Kinders, R. J.; Zhang, Y. P.; Rubinstein, L.; Kummar, S.; Parchment, R. E.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Plos One. 2011, Oct; 6(10): 8.
  1. 16.   Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
  2. Kummar, S.; Kinders, R.; Gutierrez, M. E.; Rubinstein, L.; Parchment, R. E.; Phillips, L. R.; Ji, J. P.; Monks, A.; Low, J. A.; Chen, A.; Murgo, A. J.; Collins, J.; Steinberg, S. M.; Eliopoulos, H.; Giranda, V. L.; Gordon, G.; Helman, L.; Wiltrout, R.
  3. Journal of Clinical Oncology. 2009 27(16): 2705-2711.
  1. 17.   Liquid Chromatographic Determination of NSC 737664 (ABT-888: An Inhibitor of Poly(ADP-ribose) Polymerase (PARP)) in Plasma and Urine in a Phase 0 Clinical Trial
  2. Phillips, L. R.; Hill, K. D.; Majerova, E.
  3. Journal of Liquid Chromatography & Related Technologies. 2009 32(2): 261-272.
  1. 18.   CB694, a novel antimitotic with antitumor activities
  2. Weiderhold, K. N.; Randall-Hiubek, D. A.; Polin, L. A.; Hamel, E.; Mooberry, S. L
  3. International Journal of Cancer. 2006, FEB 15; 118(4): 1032-1040.
  1. 19.   Suppression of the poly(ADP-ribose) polymerase activity by DNA-dependent protein kinase in vitro
  2. Ariumi, Y.; Masutani, M.; Copeland, T. D.; Mimori, T.; Sugimura, T.; Shimotohno, K.; Ueda, K.; Hatanaka, M.; Noda, M.
  3. Oncogene. 1999 18(32): 4616-4625.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel